BEST UNLIMITED TURBO LONG CERTIFICATE - AMGEN | Market Closed - Euronext Paris 12:30:00 2024-07-15 EDT | ||
| 9.546 EUR | -0.49% |
|
| Current month | +17.66% | ||
| 1 month | +38.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 9.546 | -0.49% |
| 24-07-12 | 9.593 | +4.42% |
| 24-07-11 | 9.187 | +4.40% |
| 24-07-10 | 8.8 | +10.76% |
| 24-07-09 | 7.945 | +0.88% |
Real-time Euronext Paris
Last update July 15, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| QM40S | |
| ISIN | DE000SW2D649 |
| Date issued | 2023-08-17 |
| Strike | 229.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.18 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.17 € |
|---|---|
| Lowest since issue | 3.417 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
330.2
USD
Average target price
317.4
USD
Spread / Average Target
-3.86%
- Stock Market
- Certificates
- QM40S Certificat
